{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:51:29Z","timestamp":1788922289216,"version":"build-2803163510"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n Importance<\/jats:title>\n Use of Medicare Advantage (MA) insurance has been associated with lower cancer treatment costs than traditional Medicare (TM). Whether there are differences in guideline-concordant care or treatment costs for beneficiaries insured under MA vs TM is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether Medicare insurance type is associated with receipt of optimal cancer treatment and costs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Retrospective cohort study of a population-based sample using Medicare claims and encounter data from 2015 through 2019. Participants were Medicare beneficiaries with continuous enrollment in either MA or TM and an incident cancer diagnosis from 2016 through 2019. Included patients were those with cancer treatment scenarios (eg, metastatic melanoma, adjuvant therapy for stage III colon cancer) that had substantial variation in the costs of recommended treatment options. Data were analyzed from April 2025 to March 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Medicare insurance type of MA or TM.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The pharmacologic cancer treatment among the available options each patient initiated was analyzed using Medicare data. Each patient\u2019s treatment was linked by diagnosis date to contemporary National Comprehensive Cancer Network Guidelines recommendations and Medicare reimbursement rates to ascertain the coprimary outcomes whether a patient received the optimal treatment for their cancer type and the anticipated cost of the initiated treatment. The association of outcomes with insurance type was accessed using generalized estimating equations to estimate risk ratios (RRs) after balancing patient characteristics through inverse probability-of-treatment weighting. Models were clustered at the physician level and adjusted for scenario, diagnosis year, scenario \u00d7 diagnosis year interaction, and oncologist characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 35\u202f245 patients (median age, 74 [IQR 70-79] years; 63.2% male), 24\u202f269 had TM and 10\u202f976 had MA. The median time to treatment initiation was 36 (IQR, 20-60) days for MA vs 35 (IQR, 19-59) days for TM. The unadjusted mean (SD) treatment cost was $29\u202f252 ($80\u202f391) for MA vs $40\u202f874 ($106 205) for TM. MA beneficiaries had a likelihood of optimal treatment similar to TM beneficiaries (adjusted RR, 0.99; 95% CI, 0.97-1.02), and MA was associated with lower treatment cost (adjusted cost ratio, 0.94; 95% CI, 0.91- 0.97). Mean savings within this patient cohort was \u2212$931 (95% CI, \u2212$1244 to \u2212$615).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of Medicare beneficiaries with cancer, MA beneficiaries had lower estimated treatment costs and similar likelihood of receiving optimal treatment compared with TM beneficiaries.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.2864","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:00:23Z","timestamp":1783954823000},"page":"1135","source":"Crossref","is-referenced-by-count":1,"title":["Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare"],"prefix":"10.1001","volume":"186","author":[{"given":"Aaron P.","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Mishra Meza","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augello","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Guzman","sequence":"additional","affiliation":[{"name":"Department of Finance, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Abdelaziz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems Outcomes and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tabatabai","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Persaud","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirjhar","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Blinder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Daly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems Outcomes and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeah","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Health Administration and Policy, College of Public Health, George Mason University, Fairfax, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ioi260037r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0859","article-title":"Measuring the scope of prior authorization policies: applying private insurer rules to Medicare Part B.","volume":"2","author":"Schwartz","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"7","key":"ioi260037r4","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.37765\/ajmc.2022.89184","article-title":"Medicare Advantage coverage restrictions for the costliest physician-administered drugs.","volume":"28","author":"Anderson","year":"2022","journal-title":"Am J Manag Care"},{"issue":"8","key":"ioi260037r5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/JCO.23.01693","article-title":"Prior authorization and association with delayed or discontinued prescription fills.","volume":"42","author":"Kyle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"ioi260037r6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1377\/hlthaff.2015.0272","article-title":"High-cost patients had substantial rates of leaving Medicare Advantage and joining traditional Medicare.","volume":"34","author":"Rahman","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"12","key":"ioi260037r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4001","article-title":"Health care utilization and spending in Medicare Advantage vs traditional Medicare: a difference-in-differences analysis.","volume":"2","author":"Schwartz","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"12","key":"ioi260037r8","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1377\/hlthaff.2012.0179","article-title":"Analysis Of Medicare Advantage HMOs compared with traditional Medicare shows lower use of many services during 2003-09.","volume":"31","author":"Landon","year":"2012","journal-title":"Health Aff (Millwood)"},{"key":"ioi260037r9","doi-asserted-by":"publisher","DOI":"10.1086\/730436","article-title":"Medicare Advantage has lower resource use and better quality of care than traditional Medicare.","author":"Jung","year":"2025","journal-title":"Am J Health Econ"},{"issue":"9","key":"ioi260037r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.34707","article-title":"Resource use and care quality differences among Medicare beneficiaries undergoing chemotherapy.","volume":"7","author":"Kalidindi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"20","key":"ioi260037r11","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1200\/JCO-24-01907","article-title":"Use of low-value cancer treatments in Medicare Advantage versus traditional Medicare.","volume":"43","author":"Jung","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi260037r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.4868","article-title":"High-cost cancer drug use in Medicare Advantage and traditional Medicare.","volume":"6","author":"Bradley","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"9","key":"ioi260037r13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jamaoncol.2015.3151","article-title":"Risk adjusting survival outcomes in hospitals that treat patients with cancer without information on cancer stage.","volume":"1","author":"Pfister","year":"2015","journal-title":"JAMA Oncol"},{"key":"ioi260037r14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084729","article-title":"Provider billing margin and cancer treatment selection: population based cohort study.","volume":"391","author":"Mitchell","year":"2025","journal-title":"BMJ"},{"issue":"1","key":"ioi260037r15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/1475-6773.13879","article-title":"Measuring resource use in Medicare Advantage using encounter data.","volume":"57","author":"Jung","year":"2022","journal-title":"Health Serv Res"},{"issue":"4","key":"ioi260037r16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/1475-6773.13970","article-title":"Implementation of resource use measures in Medicare Advantage.","volume":"57","author":"Jung","year":"2022","journal-title":"Health Serv Res"},{"issue":"1","key":"ioi260037r17","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.70062","article-title":"Provider attribution in Medicare: challenges and solutions.","volume":"61","author":"Carlin","year":"2026","journal-title":"Health Serv Res"},{"key":"ioi260037r18","doi-asserted-by":"publisher","DOI":"10.1086\/730436","article-title":"Medicare Advantage has lower resource use and better quality of care than traditional Medicare.","author":"Jung","year":"2025","journal-title":"Am J Health Econ"},{"issue":"5","key":"ioi260037r19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1200\/JCO.24.00459","article-title":"Quality of treatment selection for Medicare beneficiaries with cancer.","volume":"43","author":"Mitchell","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"ioi260037r22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40273-020-00901-x","article-title":"The accuracy and usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability rating.","volume":"38","author":"Mitchell","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"ioi260037r23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.6004\/jnccn.2020.7574","article-title":"Association between clinical value and financial cost of cancer treatments: a cross-sectional analysis.","volume":"18","author":"Mitchell","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"ioi260037r24","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00995","article-title":"Changes in cost of guideline-concordant cancer treatment: observations and implications.","author":"Wang","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"ioi260037r25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.42937","article-title":"Biologic drug prices in Medicare Part B after entry of biosimilars to the market.","volume":"8","author":"Abdelaziz","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"36","key":"ioi260037r27","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia.","volume":"34","author":"Winn","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"ioi260037r28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pds.3719","article-title":"Using claims data to predict dependency in activities of daily living as a proxy for frailty.","volume":"24","author":"Faurot","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"ioi260037r29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"key":"ioi260037r30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/POR.S197252","article-title":"Using claims data to attribute patients with breast, lung, or colorectal cancer to prescribing oncologists.","volume":"10","author":"Fishman","year":"2019","journal-title":"Pragmat Obs Res"},{"issue":"25","key":"ioi260037r31","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi260037r32","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia.","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"6","key":"ioi260037r33","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.21.01359","article-title":"Medicare Advantage: a disadvantage for complex cancer surgery patients.","volume":"41","author":"Raoof","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"ioi260037r34","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14308","article-title":"Restrictiveness of Medicare Advantage provider networks across physician specialties.","volume":"59","author":"Feyman","year":"2024","journal-title":"Health Serv Res"},{"issue":"10","key":"ioi260037r35","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.37765\/ajmc.2021.88766","article-title":"Comparison of the use of the top-ranked cancer hospitals between Medicare Advantage and traditional Medicare.","volume":"27","author":"Kim","year":"2021","journal-title":"Am J Manag Care"},{"key":"ioi260037r36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jpubeco.2016.07.003","article-title":"Who benefits when the government pays more? pass-through in the Medicare Advantage program.","volume":"141","author":"Duggan","year":"2016","journal-title":"J Public Econ"},{"issue":"6","key":"ioi260037r37","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/jnci\/djaf036","article-title":"Switching between Medicare Advantage and traditional Medicare for individuals newly diagnosed with cancer 2015-2019.","volume":"117","author":"Parsons","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"ioi260037r38","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1097\/SLA.0000000000005098","article-title":"Medicare Advantage networks and access to high-volume cancer surgery hospitals.","volume":"274","author":"Raoof","year":"2021","journal-title":"Ann Surg"},{"issue":"7","key":"ioi260037r40","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1097\/MLR.0b013e318289c3fb","article-title":"An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data.","volume":"53","author":"Whyte","year":"2015","journal-title":"Med Care"},{"issue":"8","key":"ioi260037r41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.18553\/jmcp.2024.24153","article-title":"Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives.","volume":"30","author":"Hernandez","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"ioi260037r20","first-page":"S34","article-title":"Measuring the value of new drugs: validity and reliability of 4 value assessment frameworks in the oncology setting.","volume-title":"J Manag Care Spec Pharm","author":"Bentley","year":"2017"},{"key":"ioi260037r21","first-page":"S13","article-title":"Value frameworks for the patient-provider interaction: a comparison of the ASCO Value Framework versus NCCN evidence blocks in determining value in oncology.","volume-title":"J Manag Care Spec Pharm","author":"Shah-Manek","year":"2017"},{"key":"ioi260037r1","unstructured":"Cubanski? J, Freed? M, Ochieng? N, Cottrill? A, Biniek? J, Neuman? T. Medicare 101. KFF. 2025. Accessed October 31, 2025. https:\/\/www.kff.org\/medicare\/health-policy-101-medicare\/?entry=table-of-contents-what-is-medicare"},{"key":"ioi260037r2","unstructured":"Medicare Payment Advisory Commission. March 2025 Report to the Congress: Medicare Payment Policy. March 13, 2025. Accessed October 31, 2025. https:\/\/www.medpac.gov\/document\/march-2025-report-to-the-congress-medicare-payment-policy\/"},{"key":"ioi260037r26","unstructured":"Mitchell? A. Framework for measuring cancer treatment cost and quality. Zenodo; 2026. v2. Accessed January 16, 2026. doi:10.5281\/zenodo.15101777"},{"key":"ioi260037r39","unstructured":"Jacobson? G, Trilling? A, Neuman? T, Damico? A, Gold? M. Medicare Advantage hospital networks: how much do they vary? KFF. June 20, 2016. Accessed November 21, 2025. https:\/\/www.kff.org\/affordable-care-act\/medicare-advantage-hospital-networks-how-much-do-they-vary\/"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2851378\/jamainternal_mitchell_2026_oi_260037_1788184619.76901.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:01:19Z","timestamp":1788879679000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2851378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.2864","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}